Avid Bioservices Inc (CDMO)

[biopharm]

corp, its very relevant. By now, we all are well aware that chemotherapy is going to the back of the class... and IO or Immuno-Oncology is moving to the head of the class for medical treatment. I even heard BMS publicly make this known just this past month for melanoma and it only starts there.

Dmitry Gabrilovich's research is all about Notch Signaling and MDSC's and all those cascade of events that take place that "proves" what is going on (communication among cells..) when the immune system is able to optimally perform.

What is this called when the immune system is performing at its best.... all while being treated for cancer or viral or many of the hundreds of auto-immune diseases or blood diseases...etc..etc ??

Its IO

Its Immuno-Oncology

What provides the most robust immune response ? Peregrine Pharmaceuticals PS Targeting platform which begins with Bavituximab

Pathology = the science of the causes and effects of diseases, especially the branch of medicine that deals with the laboratory examination of samples of body tissue for diagnostic or forensic purposes.

Now... corp, its important to understand that all will understand why PS Targeting works and soon. The days of FDA approving drugs on tumors stopping growth or being reduced while the cascade of events (Notch Signaling) proved the entire time that once treatment stopped for many chemo's... that disease progressed faster is amazing and why didn't Big Pharma make the FDA aware of this or why wouldn't the FDA scientific minds even investigate?

maybe because PS Targeting was not known or there was no financial incentive all those years ... but now its known, though the financial incentive would go to those who own PS TArgeting rights. Guess who has the patent rights? : )

Peregrine Pharmaceuticals

so... "CHOP cell pathology" does play into proving, in another parallel way that PS Targeting will work and work well.

maybe on diabetes as well.... actually, I'm sure it likely will

http://www.ncbi.nlm.nih.gov/pubmed/19013284